Elicio Therapeutics Stock Alpha and Beta Analysis

ELTX Stock   5.00  0.07  1.42%   
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Elicio Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Elicio Therapeutics over a specified time horizon. Remember, high Elicio Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Elicio Therapeutics' market risk premium analysis include:
Beta
(0.51)
Alpha
0.32
Risk
4.83
Sharpe Ratio
0.0887
Expected Return
0.43
Please note that although Elicio Therapeutics alpha is a measure of relative return and represented here as a single number, it indicates the percentage above or below your selected benchmark (i.e., Dow Jones Industrial index.) So in this particular case, Elicio Therapeutics did 0.32  better than the index. Remember, a high alpha is always good. Beta, on the other hand, measures the volatility (or risk) of an investment. It is an indication of Elicio Therapeutics stock's relative risk over its benchmark. Elicio Therapeutics has a beta of 0.51  . As returns on the market increase, returns on owning Elicio Therapeutics are expected to decrease at a much lower rate. During the bear market, Elicio Therapeutics is likely to outperform the market. At this time, Elicio Therapeutics' Price Book Value Ratio is fairly stable compared to the past year. Price Fair Value is likely to rise to 3.89 in 2024, whereas Book Value Per Share is likely to drop 2.14 in 2024.

Enterprise Value

34.2 Million

Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
  
Check out Elicio Therapeutics Backtesting, Elicio Therapeutics Valuation, Elicio Therapeutics Correlation, Elicio Therapeutics Hype Analysis, Elicio Therapeutics Volatility, Elicio Therapeutics History and analyze Elicio Therapeutics Performance.
For more information on how to buy Elicio Stock please use our How to Invest in Elicio Therapeutics guide.

Elicio Therapeutics Market Premiums

Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Elicio Therapeutics market risk premium is the additional return an investor will receive from holding Elicio Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Elicio Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Elicio Therapeutics' performance over market.
α0.32   β-0.51

Elicio Therapeutics expected buy-and-hold returns

Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Elicio Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Elicio Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.

Elicio Therapeutics Market Price Analysis

Market price analysis indicators help investors to evaluate how Elicio Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Elicio Therapeutics shares will generate the highest return on investment. By understating and applying Elicio Therapeutics stock market price indicators, traders can identify Elicio Therapeutics position entry and exit signals to maximize returns.

Elicio Therapeutics Return and Market Media

The median price of Elicio Therapeutics for the period between Tue, Aug 27, 2024 and Mon, Nov 25, 2024 is 4.75 with a coefficient of variation of 9.22. The daily time series for the period is distributed with a sample standard deviation of 0.43, arithmetic mean of 4.65, and mean deviation of 0.36. The Stock received substential amount of media coverage during this period.
 Price Growth (%)  
       Timeline  
1
Elicio Therapeutics CFO Brian Piekos Resigns Amicably - TipRanks
08/30/2024
2
Acquisition by Haqq Christopher of 28200 shares of Elicio Therapeutics at 5.03 subject to Rule 16b-3
09/30/2024
3
All You Need to Know About Elicio Therapeutics Rating Upgrade to Strong Buy
10/24/2024
4
SEC Form 424B3 filed by Elicio Therapeutics Inc. - Quantisnow
11/22/2024

About Elicio Therapeutics Beta and Alpha

For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Elicio or other stocks. Alpha measures the amount that position in Elicio Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
 2023 2024 (projected)
Graham Number18.7717.83
Receivables Turnover33.8917.01

Elicio Therapeutics Upcoming Company Events

As portrayed in its financial statements, the presentation of Elicio Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Elicio Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Elicio Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Elicio Therapeutics. Please utilize our Beneish M Score to check the likelihood of Elicio Therapeutics' management manipulating its earnings.
15th of March 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
15th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Build Portfolio with Elicio Therapeutics

Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.

Build Diversified Portfolios

Align your risk with return expectations

By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations

Additional Tools for Elicio Stock Analysis

When running Elicio Therapeutics' price analysis, check to measure Elicio Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Elicio Therapeutics is operating at the current time. Most of Elicio Therapeutics' value examination focuses on studying past and present price action to predict the probability of Elicio Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Elicio Therapeutics' price. Additionally, you may evaluate how the addition of Elicio Therapeutics to your portfolios can decrease your overall portfolio volatility.